Covid-19 pill could add an­oth­er $15-25B to Pfiz­er's al­ready tor­rid pan­dem­ic cash flow — an­a­lyst

If you thought Pfiz­er was rak­ing it in with megablock­buster sales of its BioN­Tech-part­nered Covid-19 vac­cine — last pro­ject­ed at $36 bil­lion for 2021 — think again.

As the phar­ma gi­ant sends off its EUA sub­mis­sion for its an­tivi­ral pill to the FDA, the Wash­ing­ton Post, New York Times and oth­ers are re­port­ing that the US gov­ern­ment is plan­ning a $5 bil­lion con­tract to pur­chase 10 mil­lion cours­es of the treat­ment, dubbed Paxlovid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER